the aid library

LIST OPTIONS

Filter

13929

Download (446)

View PDF (586)

WHO operational handbook on tuberculosis: module 2: screening: systematic screening for tuberculosis disease

World Health Organization WHO (2020) C_WHO

Download (315)

View PDF (420)

WHO global report on trends in prevalence of tobacco use 2000-2025

World Health Organization WHO (2021) C_WHO

Progress in reducing tobacco use is a key indicator for measuring countries’ efforts to implement the WHO Framework Convention on Tobacco Control – target 3.a under the Sustainable Development Goals agenda. Countries have adopted this indicator to report progress also towards the tobacco reducti... more

Download (224)

View PDF (246)

South Africa - Country Cooperation Strategy 2023 - 2027

World Health Organization WHO (2025) C_WHO

The South African WHO Country Cooperation Strategy (CCS) 2023–2027 focuses on four key strategic priorities based on the country’s health needs and disease epidemiology, while also considering the need for building resilient health systems for UHC and health security in the post pandemic period.... more

Download (420)

View PDF (492)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (818)

View PDF (1169)

Independent Monitoring Board of the Global Polio Eradication Initiative (Fifteenth Report: December 2017)

Global Polio Eradication Initiative (2017) C1

The report reviews progress with the task of planning and implementing measures necessary to secure a completely polio-free world. It also examines actions aimed at ensuring successful transfer of polio assets, innovations developed and lessons learned to countries’ public health programmes and ot... more

Download (3253)

View PDF (1053)

Sierra Leone: National Community Health Worker Policy 2016–2020

Ministry of Health and Sanitation of Sierra Leone (2016) C1

External Link

WHO Disability Assessment Schedule 2.0 (WHODAS 2.0)

World Health Organization (WHO) (2017) C_WHO

The new WHODAS 2.0 supersedes WHODAS II and shows the following advantages: - A generic assessment instrument for health and disability - Used across all diseases, including mental, neurological and addictive disorders - Short, simple and easy to administer (5 to 20 minutes) - Applicable in both... more

External Link

Guide to introducing human rabies vaccine into national immunization programmes: Handbook

World Health Organization WHO (2022) C_WHO

Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in children.

Download (586)

View PDF (853)

Factors Associated with Changes in Uptake of HIV Testing among Young Women (age 15–24) in Tanzania from 2003 to 2012

Phimemon, Rune N., Michael J. Mahande, and Habib O. Ramadhani ICF International (2015) C2

DHS Working Papers No. 119

Download (884)

View PDF (1897)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (317)

View PDF (328)

TB Advocacy Guide - For People who use Drugs

hit.org.uk; INPUD (2019) C2

Accessed: 19.10.2019

Download (361)

View PDF (380)

EMTCT Plus - Framework for Elimination of Mother-to-Child Transmission of HIV, Syphilis, Hepatitis B, and Chagas

F. Pérez; M. B. Mello; L. Sereno; et al. Pan American Health Organization; World Health Organization (2017) C_WHO

The objective of the EMTCT Plus initiative is to achieve and sustain the elimination of mother-to-child transmission of HIV, syphilis, Chagas, and perinatal hepatitis B (HBV) as a public health threat. It embraces the principles and lines of action of the Strategy for Universal Access to Health a... more

Download (515)

View PDF (734)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (397)

View PDF (409)

Manual for male circumcision under local anaesthesia and HIV prevention services for adolescent boys and men
recommended

World Health Organization WHO (2018) C_WHO

Download (902)

View PDF (1244)

Ghana National Health Insurance Scheme Improving Financial Sustainability Based on Expenditure Review

Huihui Wang, Nathaniel Otoo, and Lydia Dsane-Selby World Bank Group (2017) C1

Download (383)

View PDF (516)

Improving Prison Conditions by Strengthening the Monitoring of HIV, HCV, TB and Harm Reduction (Portugal)

N. H. Ponters, A. P. Dores CIES IUL; ISCTE IUL; European Union (2015) C2

Mapping Report - Portugal

Download (351)

View PDF (295)

Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy

World Health Organization WHO (2022) C_WHO

WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi... more